study,trt,class,mean,sd,se,n
ang 2013,cognitive behavioural therapy ,nonad,-11.16,,4.05,15
ang 2013,cognitive behavioral therapy and milnacipran standard,snri,-15.2,,3.89,17
ang 2013,milnacipran standard,snri,-12.7,,3.89,17
arnold 2002,placebo,placebo,2.9,13.6,,26
arnold 2002,fluoxetine unable to be categorised,ssri,-8.6,14.5,,25
arnold 2004,placebo,placebo,-7.93,,1.73,102
arnold 2004,duloxetine high,snri,-13.46,,1.82,101
arnold 2005,placebo,placebo,-8.35,,1.53,115
arnold 2005,duloxetine standard,snri,-16.72,,1.53,114
arnold 2005,duloxetine high,snri,-16.81,,1.54,112
arnold 2010: 1,placebo,placebo,-8.07,,1.54,132
arnold 2010: 1,esreboxetine unable to be categorised,snri,-15.63,,1.56,128
arnold 2010: 2,placebo,placebo,-7.12,1.08,,509
arnold 2010: 2,milnacipran standard,snri,-12.34,1.09,,516
arnold 2012: 1,placebo,placebo,-10.39,,1.41,153
arnold 2012: 1,duloxetine low,snri,-14.78,,1.41,153
atkinson 1998,placebo,placebo,0.03,0.05,,40
atkinson 1998,nortriptyline unable to be categorised,tca,0.02,0.05,,38
bateman 2011,milnacipran unable to be categorised,snri,0.75,,2.57,79
bateman 2011,placebo,placebo,3.05,,6.25,21
branco 2010,placebo,placebo,-11.18,,0.99,446
branco 2010,milnacipran high,snri,14.18,,1.03,430
chappell 2008,placebo,placebo,-0.05,,0.02,160
chappell 2008,duloxetine high,snri,-0.1,,0.03,146
chappell 2009: 1,duloxetine standard,snri,-0.69,,1.82,104
chappell 2009: 1,duloxetine high,snri,3.49,,1.34,203
clauw 2008,placebo,placebo,-12,,1,401
clauw 2008,milnacipran standard,snri,-16.6,,1,399
clauw 2008,milnacipran high,snri,-15.4,,1,396
enomoto 2018,pregabalin ,nonad,-0.1,,0.01,149
enomoto 2018,duloxetine low,snri,-0.11,,0.01,152
gao 2010,placebo,placebo,-0.1,,0.02,109
gao 2010,duloxetine high,snri,-0.12,,0.02,106
goldstein 2005,placebo,placebo,-0.08,,0.02,107
goldstein 2005,duloxetine low,snri,-0.1,,0.02,101
goldstein 2005,duloxetine standard,snri,-0.13,,0.02,104
goldstein 2005,duloxetine high,snri,-0.13,,0.02,105
murakami 2015,placebo,placebo,-13.05,,2.65,195
murakami 2015,duloxetine standard,snri,-18.41,,2.57,191
rowbotham 2012,placebo,placebo,-0.07,,0.02,49
rowbotham 2012,duloxetine standard,snri,-0.07,,0.02,55
rowbotham 2012,abt-894 ,nonad,-0.07,,0.02,60
rowbotham 2012,abt-894 ,nonad,-0.07,,0.02,53
rowbotham 2012,abt-894 ,nonad,-0.07,,0.02,53
russell 2008,placebo,placebo,-10.42,,1.46,144
russell 2008,duloxetine standard,snri,-14.77,,1.88,79
russell 2008,duloxetine standard,snri,-12.28,,1.44,150
russell 2008,duloxetine high,snri,-13.86,,1.41,147
shinichi 2016,placebo,placebo,-0.08,,0.01,226
shinichi 2016,duloxetine standard,snri,-0.09,,0.01,230
skljarevski 2009,placebo,placebo,-0.05,,0.01,104
skljarevski 2009,duloxetine low,snri,-0.04,,0.02,54
skljarevski 2009,duloxetine standard,snri,-0.07,,0.01,102
skljarevski 2009,duloxetine high,snri,-0.08,,0.02,100
skljarevski 2010: 1,placebo,placebo,-0.11,0.3,,102
skljarevski 2010: 1,duloxetine high,snri,-0.16,0.32,,101
skljarevski 2010: 2,placebo,placebo,-0.05,0.17,,192
skljarevski 2010: 2,duloxetine standard,snri,-0.12,0.21,,190
smith 2013,placebo,placebo,-0.87,9.67,,94
smith 2013,duloxetine standard,snri,-2.44,9.57,,87
uchio 2018,placebo,placebo,-0.07,,0.01,176
uchio 2018,duloxetine standard,snri,-0.12,,0.01,177
vollmer 2014,placebo,placebo,-5.1,,1.1,121
vollmer 2014,duloxetine standard,snri,-6.1,,1.2,118
wernicke 2006,placebo,placebo,-0.08,,0.02,99
wernicke 2006,duloxetine standard,snri,-0.15,,0.02,108
wernicke 2006,duloxetine high,snri,-0.15,,0.02,105